Cargando…

Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin

Digoxin is widely used to treat heart failure. Epidemiological studies suggested it might be used as an anticancer drug or sensitizing agent for cancer therapy. Adriamycin is a well-known anticancer drug, but often causes cardiotoxicity which limits its use. We recently investigated the anticancer e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yingying, Ma, Qian, Zhang, Shaolu, Liu, Hongyan, Zhao, Baoquan, Du, Bo, Wang, Wei, Lin, Peng, Zhang, Zhe, Zhong, Yuxu, Kong, Dexin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059749/ https://www.ncbi.nlm.nih.gov/pubmed/32180730 http://dx.doi.org/10.3389/fphar.2020.00186

Ejemplares similares

DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway
por: Wang, Zhengming, et al.
Publicado: (2018)

Corrigendum: DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway
por: Wang, Zhengming, et al.
Publicado: (2020)

Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
por: Zhu, Hong, et al.
Publicado: (2014)

Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway
por: Wang, Yingying, et al.
Publicado: (2021)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

The effect of digoxin on the binding of adriamycin to cat heart muscle.
por: Somberg, J., et al.
Publicado: (1977)

Interaction between Chinese medicine and digoxin: Clinical and research update
por: Zhuang, Wei, et al.
Publicado: (2023)

Adriamycin cardiotoxicity monitoring by radionuclide scan.
por: Robinson, B. A., et al.
Publicado: (1983)

Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.
por: Klugmann, F. B., et al.
Publicado: (1986)

Protective effect of melatonin against Adriamycin-induced cardiotoxicity
por: ZHANG, YAN, et al.
Publicado: (2013)

Protective effects and mechanisms of psoralidin against adriamycin-induced cardiotoxicity
por: Liang, Zhenxing, et al.
Publicado: (2021)

Letter: Digoxin does not prevent daunorubicin or adriamycin from binding to rat heart muscle.
por: Smith, B. J., et al.
Publicado: (1976)

Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells
por: Zhang, Lei, et al.
Publicado: (2019)

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

Salvianolic Acid A Ameliorates Arsenic Trioxide-Induced Cardiotoxicity Through Decreasing Cardiac Mitochondrial Injury and Promotes Its Anticancer Activity
por: Zhang, Jing-yi, et al.
Publicado: (2018)

Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

Engineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma
por: Hou, Yulin, et al.
Publicado: (2023)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
por: Lai, Kuan-Cheng, et al.
Publicado: (2018)

Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
por: Szabó, Zoltán, et al.
Publicado: (2021)

Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy
por: Arzt, Madelyn, et al.
Publicado: (2023)

Safety profile of intravenous digoxin in Chinese patients with acute heart failure with reduced ejection fraction: a small-scale prospective cohort study
por: Liu, Xintian, et al.
Publicado: (2023)

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer
por: Ren, Boxue, et al.
Publicado: (2019)

Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery
por: Keung, Wendy, et al.
Publicado: (2021)

Hydropersulfides (RSSH) attenuate doxorubicin-induced cardiotoxicity while boosting its anticancer action
por: Pharoah, Blaze M., et al.
Publicado: (2023)

Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021)

Protective Role of Enalapril in Anthracycline-Induced Cardiotoxicity: A Systematic Review
por: Zhang, Yili, et al.
Publicado: (2020)

PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1
por: Wang, Wei, et al.
Publicado: (2020)

Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
por: Fu, Bingjie, et al.
Publicado: (2022)

Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies
por: Zhai, Ruonan, et al.
Publicado: (2022)

Protective Mechanism of Hydrogen Sulfide against Chemotherapy-Induced Cardiotoxicity
por: Du, Shuxu, et al.
Publicado: (2018)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
por: Qin, Lu-Yun, et al.
Publicado: (2022)

Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis
por: Tai, Chi-Jung, et al.
Publicado: (2021)

A Visual Resolution of Cardiotoxicity: A Case Report of Digoxin-Induced Bidirectional Ventricular Tachycardia
por: Phyu Phyu Aung, Thin, et al.
Publicado: (2021)

Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
por: Lin, Xiaoxiao, et al.
Publicado: (2023)

Cardiotoxicity of Anticancer Therapeutics
por: Dong, Jerry, et al.
Publicado: (2018)

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
por: Chen, Junyu, et al.
Publicado: (2022)

The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014)

Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018)

An Updated Meta-Analysis Based on the Preclinical Evidence of Mechanism of Aconitine-Induced Cardiotoxicity
por: Jiang, Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_62del9krqjv5qldstdfvjaml5d